PT - JOURNAL ARTICLE AU - Xiong, Wei AU - Zeng, Zhao Yang AU - Xia, Jia Hui AU - Xia, Kun AU - Shen, Shou Rong AU - Li, Xiao Ling AU - Hu, Dong Xu AU - Tan, Chen AU - Xiang, Juan Juan AU - Zhou, Jie AU - Deng, Hao AU - Fan, Song Qing AU - Li, Wei Fang AU - Wang, Rong AU - Zhou, Ming AU - Zhu, Shi Guo AU - Lü, Hong Bin AU - Qian, Jun AU - Zhang, Bi Cheng AU - Wang, Jie Ru AU - Ma, Jian AU - Xiao, Bing Yi AU - Huang, He AU - Zhang, Qiu Hong AU - Zhou, Yan Hong AU - Luo, Xiao Min AU - De Zhou, Hou AU - Yang, Yi Xin AU - Dai, He Ping AU - Feng, Guo Yin AU - Pan, Qian AU - Wu, Ling Qian AU - He, Lin AU - Li, Gui Yuan TI - A Susceptibility Locus at Chromosome 3p21 Linked to Familial Nasopharyngeal Carcinoma AID - 10.1158/0008-5472.CAN-03-3253 DP - 2004 Mar 15 TA - Cancer Research PG - 1972--1974 VI - 64 IP - 6 4099 - http://cancerres.aacrjournals.org/content/64/6/1972.short 4100 - http://cancerres.aacrjournals.org/content/64/6/1972.full SO - Cancer Res2004 Mar 15; 64 AB - Nasopharyngeal carcinoma (NPC) poses one of the serious health problems in southern Chinese, with an incidence rate ranging from 15 to 50/100,000. Chromosome translocation t(1;3) and frequent loss of heterogeneity on short arms of chromosome 3 and 9 have been reported to be associated with NPC, and a genome-wide scan identified an NPC susceptibility locus on chromosome 4p15.1-q12 recently. In our study, we collected samples from 18 families at high risk of NPC from the Hunan province in southern China, genotyped with a panel of polymorphic markers on short arms of chromosomes 3, 9, and 4p15.1-q12. A locus on 3p21 was identified to link to NPC with a maximum logarithm of odds for linkage score of 4.18. Fine mapping located the locus to a 13.6-cM region on 3p21.31-21.2, where a tumor suppressor gene cluster resided. Our findings identified a novel locus for NPC and provided a map location for susceptibility genes candidates. In contrast to a recent study, no significant evidence for NPC linkage to chromosomes 4 and 9 was observed. ©2004 American Association for Cancer Research.